Lochhamer Str. 11
Tel: 49-89-85 65 29-00
Fax: 49-89-85 65 29-20
218 articles with MediGene AG
Medigene AG announces that two scientific posters with preclinical data on an HA-1-specific T-cell receptor and a NY-ESO-1/LAGE-1-specific T-cell receptor were shown on 21 May 2019 during the CIMT Annual Meeting in Mainz.
Martinsried/Munich Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, reports on the Company's Annual General Meeting which was held in Munich.
Medigene AG: Medigene announces clinical trial agreement for HA-1 TCR immunotherapy MDG1021 with University of Leiden
Medigene AG announced that it entered into a Clinical Trial Agreement with the Leiden University Medical Center, the Netherlands, to conduct a Phase I clinical trial with Medigene's T cell receptor modified T cell therapy MDG1021 targeting the HA-1 antigen.
Medigene AG: Medigene to present interim data analysis from Phase I/II DC-Vaccine trial at the EHA conference 2019
Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, will present data from the interim analysis of the ongoing Phase I / II clinical trial with Medigene's DC vaccine during the annual congress of the European Hematology Association taking place from 13 - 16 June in Amsterdam.
Conference call and webcast (in English) today, May 14, 2019 at 3:00 pm CET / 9:00 am EST
Medigene AG: bluebird presents preclinical data of first TCR candidate from Medigene collaboration. Start clinical development 2020
Medigene AG announced that the Company's strategic partner bluebird bio, Inc. (NASDAQ:BLUE), USA, at its analyst day presentation, will present preclinical data of the first therapeutic T cell receptor (TCR) candidate resulting from the research and development partnership with Medigene.
Medigene AG announced its participation at the following upcoming scientific, business development and investor conferences
Medigene AG: Medigene presented data on favorable safety pattern of PRAME-specific TCR on neuronal cells at 2019 ASGCT Meeting
Functional 2D and 3D in vitro assays using neuronal cells derived from iPSCs to assess the potential risk of TCR-mediated neurotoxicity
Aresus takes over Veregen® business including API stock and intends to invest in expanding Veregen® into indications and markets
Medigene AG announced its participation at the following upcoming networking and scientific conferences
Medigene AG: Medigene presented selective killing of tumor cells by PRAME TCR-transduced T cells at AACR
3D co-cultured healthy cells survive in method for evaluation of TCR efficacy and toxicity
Conference call and webcast, March 27, 2019 at 3pm CET (Frankfurt) / 10am EST (New York)
High-throughput assessment of neoantigens recognized by both CD8+ and CD4+ T cells presented at Immuno-Oncology Summit Europe
Medigene AG (FSE: MDG1, Prime Standard, SDAX) today publishes preliminary financial results for the financial year 2018.
Medigene AG announced that researchers of the Company will present a poster at the 2019 American Association for Cancer Research Annual Meeting.
Medigene AG: Medigene announces dosing of first patient in Phase I/II trial with TCR therapy MDG1011 for various blood cancers
Medigene AG announced that it has dosed the first patient in its first-in-human clinical trial with its TCR therapy candidate MDG1011.
Medigene AG: European Patent covering TCR library suitable for the development of neoantigen-specific TCRs
Medigene AG reported that the European Patent Office intends to grant a European Patent for the patent application EP3303591A1 covering a T cell receptor building block library that is suitable for rapid reconstruction and testing of newly discovered TCR sequences against classical antigens as well as neoantigens.
Planegg Medigene AG announced its participation at the following upcoming scientific conferences
Medigene AG announced that its Supervisory Board has appointed Axel-Sven Malkomes as Chief Financial Officer and Chief Business Development Officer effective 1 April 2019.
Medigene AG announced its participation at the following upcoming investor and scientific conferences